Welcome to LookChem.com Sign In|Join Free
  • or
Home > Products >  > 

Oxanamide

Related Products

Hot Products

Basic Information Post buying leads Suppliers
Name

Oxanamide

EINECS N/A
CAS No. 126-93-2 Density 1.028g/cm3
PSA 56.61000 LogP 1.96910
Solubility N/A Melting Point 90-91°
Formula C8H15 N O2 Boiling Point 292.2°Cat760mmHg
Molecular Weight 157.213 Flash Point 145.8°C
Transport Information N/A Appearance N/A
Safety Moderately toxic by ingestion and intraperitoneal routes. When heated to decomposition it emits toxic fumes of NOx. Risk Codes N/A
Molecular Structure Molecular Structure of 126-93-2 (Oxanamide) Hazard Symbols N/A
Synonyms

Hexanamide,2,3-epoxy-2-ethyl- (6CI,7CI,8CI); Oxiranecarboxamide, 2-ethyl-3-propyl- (9CI);2,3-Epoxy-2-ethylhexanamide; 2-Ethyl-3-propyl-2,3-epoxypropionamide;2-Ethyl-3-propylglycidamide; Oxanamid; Oxanamide; Quiactin

 

Oxanamide Chemical Properties

IUPAC Name: 2-Ethyl-3-propyloxirane-2-carboxamide
Synonyms of Oxanamide (CAS NO.126-93-2) : Oxanamide ; 2-Ethyl-3-propyl-2-oxiranecarboxamide ; 2-Ethyl-3-propyloxiranecarboxamide ; 2-Oxiranecarboxamide, 2-ethyl-3-propyl-
CAS NO:126-93-2
Molecular Formula:C8H15NO2
Molecular Weight:157.2102
Molecular Structure:
Index of Refraction: 1.463
Surface Tension: 34.5 dyne/cm
Density: 1.028 g/cm3
Flash Point: 145.8 °C
Enthalpy of Vaporization: 53.17 kJ/mol
Boiling Point: 292.2 °C at 760 mmHg
Vapour Pressure: 0.00186 mmHg at 25°C

Oxanamide Uses

 Oxanamide (CAS NO.126-93-2) is an anxiolytic and muscle relaxant medication which can produce sedative and hypnotic effects in sufficiently high doses. It was efficacious in the treatment of anxiety resulting from premenstrual syndrome, menopause, and various other causes, with minimal sedation or other side effects.

Oxanamide Toxicity Data With Reference

Organism Test Type Route Reported Dose (Normalized Dose) Effect Source
mouse LD50 intraperitoneal 605mg/kg (605mg/kg)   Journal of Pharmacology and Experimental Therapeutics. Vol. 134, Pg. 60, 1961.
mouse LD50 oral 1220mg/kg (1220mg/kg) BRAIN AND COVERINGS: RECORDINGS FROM SPECIFIC AREAS OF CNS

BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX)

BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)
Proceedings of the Society for Experimental Biology and Medicine. Vol. 103, Pg. 101, 1960.
rabbit LD50 intravenous > 360mg/kg (360mg/kg)   Journal of Pharmacology and Experimental Therapeutics. Vol. 96, Pg. 209, 1949.
rat LD50 oral 1250mg/kg (1250mg/kg) BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) Federation Proceedings, Federation of American Societies for Experimental Biology. Vol. 7, Pg. 262, 1948.

Oxanamide Safety Profile

Moderately toxic by ingestion and intraperitoneal routes. When heated to decomposition it emits toxic fumes of NOx.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 126-93-2